Finally, our compounds inhibited cancer cell growth at low micromolar concentrations, similar to the clinically evaluated 17-DMAG, and our lead compound was able to reduce intracellular levels of Hsp90 dependent client proteins without significant HSR induction. Here, HSP90AB1 is linked to cancer.